--- title: "Doximity reports November 5: growth slowed from 23.2% to 7.3% while a securities suit names its CEO" description: "Doximity reports fiscal Q2 on November 5 while a securities class action over its Newsfeed claims heads toward a November 16 deadline, and its newest product, the AI safety layer DoseCheck, shipped free three days before the print with no published price." publisher: "The Inference" section: "Health" published: 2026-11-02T16:51:22.000Z modified: 2026-11-02T16:51:22.000Z canonical: https://theinference.org/article/doximity-reports-november-5-growth-slowed-from-23-2-to-7-3-while-a-securities-suit-names-its-ceo language: en keywords: "Doximity, Health Tech, Earnings, Securities Litigation, Medical AI" --- # Doximity reports November 5: growth slowed from 23.2% to 7.3% while a securities suit names its CEO > Doximity reports fiscal Q2 on November 5 while a securities class action over its Newsfeed claims heads toward a November 16 deadline, and its newest product, the AI safety layer DoseCheck, shipped free three days before the print with no published price. ## The suit that reached the chief executive's desk [Doximity](https://theinference.org/markets/companies/doximity) reports [fiscal second-quarter results](https://investors.doximity.com/news/news-details/2026/Doximity-to-Release-Fiscal-2027-Second-Quarter-Results-on-November-5-2026/default.aspx) after the close on Thursday, November 5 [3]. In the background sits [a securities class action](https://scanx.trade/stock-market-news/companies/doximity-sued-class-action-alleged-ad-fraud/51137263) that names CEO [Jeffrey Tangney](https://theinference.org/markets/people/jeffrey-tangney), former CFO [Anna Bryson](https://theinference.org/markets/people/anna-bryson), Chief Strategy Officer Nate Gross and investor-relations chief Perry Gold as defendants alongside the company itself [1]. The suit alleges Doximity oversold its Newsfeed as the "biggest revenue driver" while relying on banner ads and email newsletters it publicly claimed it did not use, and while losing share to cheaper rivals [1][5]. Holders who bought between August 8, 2024, and May 13, 2026, have [until November 16 to seek the lead-plaintiff role](https://macaubusiness.com/docs-deadline-rosen-a-longstanding-firm-encourages-doximity-inc-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline-in-securities-class-action-docs/) [5]. ## $19.26 a share, gone in three sessions The complaint's receipts are the stock itself. Doximity fell 13% on November 6, 2025, after warning on ad spending, 17% on February 5, 2026, after cutting fiscal 2026 revenue guidance, and 23% on May 13, 2026, after missing the already-reduced guide, a combined $19.26 per share ending at an all-time closing low of $18.01 [1]. *Chart: **Three one-day declines stripped $19.26 a share from Doximity** Bars showing three one-day share price declines: $8.29 on November 6 2025, $5.59 on February 5 2026, $5.38 on May 13 2026, totaling $19.26* *One-day share price declines in US dollars per share, on the trading days after each disclosure, as compiled by Levi & Korsinsky in the class action record. Source: scanx.trade, October 30, 2026. [1]* The stock has since roughly doubled, trading near $32.76 on November 2 [8]. That rally is what Thursday's print has to defend. ## The complication: engagement again, monetization never On October 29, three days before earnings, Doximity [launched DoseCheck, a free AI dosing-safety layer for its Ask tool](https://www.stocktitan.net/news/DOCS/doximity-launches-dose-check-to-catch-dangerous-ai-drug-dosing-fjasyrsrnc99.html), with no published price [2]. Its own benchmark is the strongest sales document and the sharpest confession in the record: across nine widely used AI models and more than 8,000 real physician questions, at least 2.3% of dosing claims were wrong, and 43.8% of the errors were serious or potentially lethal [2][7]. The pattern should feel familiar. DoseCheck deepens engagement the same usage-first way the suit says the Newsfeed did, on a cost-per-target subscription model whose monetization the plaintiffs claim quietly decelerated [1]. ## From 23.2% growth to 7.3% in four quarters Doximity's [SEC filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001516513) carry the deceleration the suit alleges. Year-over-year revenue growth ran 23.2% in the quarter ended September 2025, then 9.8%, then 5.1%, then 7.3% in the quarter ended June 2026; net income fell 54% year over year in that last reported quarter [6]. *Chart: **Doximity's revenue growth ran at 23% a year ago and 7% last quarter** Line chart of Doximity's year-over-year quarterly revenue growth from 6.4% in March 2024 to a peak of 24.6% in December 2024, down to 5.1% and 7.3% in the two most recent quarters* *Revenue growth, year over year, by fiscal quarter, from Doximity's SEC filings, retrieved November 2, 2026. Labels follow the calendar quarter each fiscal period ended. Source: SEC filings via company data series. [6]* *Chart: **Net income has fallen from a $75M peak to $24M last quarter** Column chart of Doximity's quarterly net income from $30.6 million in Q3 2023 to a peak of $75.2 million in Q4 2024, falling to $24.32 million in Q2 2026* *Quarterly net income in US dollars millions, by calendar quarter each fiscal period ended, from Doximity's SEC filings, retrieved November 2, 2026. Source: SEC filings via company data series. [9]* Thursday's quarter ended September 30, 2026, against a year-ago quarter that grew 23.2% [4]. Anything near June's 7.3% is a third straight disappointment, and [analyst models assume only 6.6% yearly revenue growth to 2029](https://sg.finance.yahoo.com/news/dosecheck-launch-change-doximity-docs-071115331.html) [4]. ## The bull case has receipts too The company side is not a shrug. Doximity reaches more than 85% of US doctors, its Clinical AI Suite runs in over 165 health systems including 10 of the top 20 hospitals [2], and it ranked top among US clinical AI models in the Stanford and Harvard NOHARM study [2]. Trailing free cash flow runs about $298 million, and Simply Wall St's [fair-value model](https://finance.yahoo.com/markets/stocks/articles/doximity-docs-priced-dosecheck-launch-060918437.html) puts the stock roughly in line with cash flows, about 6% downside from $32.76 [8][4]. Even the bear camp's own summary names the risk precisely: "the thesis that new AI products can be given away initially and monetized later is still unproven" [8]. ## Three dates decide it November 5 answers whether engagement converts to pharma subscription revenue at anywhere near last year's pace [5]. November 16 closes the lead-plaintiff window [5]. And the UpToDate integration, which likewise shipped with no price in October (/article/doximity-put-wolters-kluwer-s-uptodate-inside-its-ask-tool-for-health-systems-and-named-no-price), now needs a number. Free tools built the complaint's case; free tools are the company's counterattack; only Thursday's revenue line can tell them apart. ## Takeaway Thursday's print has to show the engagement-heavy strategy converting to revenue: free AI products built the plaintiffs' case and free AI products are the company's counterattack, and only the revenue line separates them. ## Sources 1. [scanx.trade, Doximity sued in class action over alleged ad fraud, 30 October 2026](https://scanx.trade/stock-market-news/companies/doximity-sued-class-action-alleged-ad-fraud/51137263) 2. [Stock Titan, Doximity Launches DoseCheck to Catch Dangerous AI Drug Dosing Errors, 29 October 2026](https://www.stocktitan.net/news/DOCS/doximity-launches-dose-check-to-catch-dangerous-ai-drug-dosing-fjasyrsrnc99.html) 3. [Doximity Investor Relations, Doximity to Release Fiscal 2027 Second Quarter Results on November 5, 2026, 15 October 2026](https://investors.doximity.com/news/news-details/2026/Doximity-to-Release-Fiscal-2027-Second-Quarter-Results-on-November-5-2026/default.aspx) 4. [Simply Wall St via Yahoo Finance Singapore, Will DoseCheck Launch Change Doximity (DOCS) Narrative, 2 November 2026](https://sg.finance.yahoo.com/news/dosecheck-launch-change-doximity-docs-071115331.html) 5. [Rosen Law Firm via GlobeNewswire and Macau Business, Doximity investors with losses in excess of $100K, 31 October 2026](https://macaubusiness.com/docs-deadline-rosen-a-longstanding-firm-encourages-doximity-inc-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline-in-securities-class-action-docs/) 6. [Doximity quarterly figures from SEC filings, retrieved 2 November 2026](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001516513) 7. [Fierce Healthcare, Weekly Rundown: Doximity launches DoseCheck, 30 October 2026](https://www.fiercehealthcare.com/health-tech/weekly-rundown-doximity-launches-dosecheck-ai-recommends-costlier-care-doctors-study) 8. [Simply Wall St via Yahoo Finance, Is Doximity (DOCS) Priced Right After Its DoseCheck Launch, 2 November 2026](https://finance.yahoo.com/markets/stocks/articles/doximity-docs-priced-dosecheck-launch-060918437.html) 9. [Doximity, quarterly figures from its SEC filings, retrieved 2 November 2026](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001516513) --- Doximity reports November 5: growth slowed from 23.2% to 7.3% while a securities suit names its CEO — The Inference. Canonical: https://theinference.org/article/doximity-reports-november-5-growth-slowed-from-23-2-to-7-3-while-a-securities-suit-names-its-ceo